Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
A 13-year-old spayed female dog was referred for a history of tachypnea and dyspnea. Severe pulmonary hypertension was diagnosed based on tricuspid regurgitation velocities and 2-dimensional echocardiography. Left atrial size was normal at the time of this diagnosis. However, following treatment with a selective phosphodiesterase inhibitor, echocardiography revealed unmasking of left heart dilation. Key clinical message: If phosphodiesterase inhibition therapy is deemed appropriate in patients with hemodynamically important myxomatous mitral valvular disease, using the lowest effective dosage and careful monitoring with echocardiography ± thoracic radiographs should be considered.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543657 | PMC |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!